Using DOACs for Valvular Atrial Fibrillation - Frankly Speaking Ep 249

10:42
 
Share
 

Manage episode 306585709 series 1338191
By Kevin Foley. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Credits: 0.25 AMA PRA Category 1 Credit™

CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-249

Overview: For non-valvular atrial fibrillation, physicians, patients, and guideline organizations all prefer direct oral anticoagulants (DOACs) over vitamin K antagonists, such as warfarin, for thromboembolic prophylaxis. For those with valvular atrial fibrillation, the data for safety and efficacy have been limited because randomized trials comparing DOACs to warfarin often exclude patients with valvular atrial fibrillation. Join us to explore new data that shed light on the use of DOACs in valvular atrial fibrillation.

Episode resource links:

  • Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. Ann Intern Med. 2021;174(7):910-919.

Guest: Alan Ehrlich MD, FAAFP

Music Credit: Richard Onorato

270 episodes